This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile, Expert Opinion on Drug Safety, July 2007, Informa Healthcare,
DOI: 10.1517/14740338.6.4.397.
You can read the full text:
The following have contributed to this page
